InflaRx (IFRX) Cash & Equivalents (2022 - 2025)

InflaRx (IFRX) has disclosed Cash & Equivalents for 4 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 92.44% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 92.44% year-over-year, with the annual reading at $1.5 million for FY2025, 92.44% down from the prior year.
  • Cash & Equivalents hit $1.5 million in Q4 2025 for InflaRx, down from $19.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $19.7 million in Q4 2024 to a low of $1.5 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $12.9 million across 4 years, with a median of $15.2 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: surged 43.13% in 2024 and later crashed 92.44% in 2025.
  • Year by year, Cash & Equivalents stood at $16.6 million in 2022, then fell by 17.22% to $13.7 million in 2023, then skyrocketed by 43.13% to $19.7 million in 2024, then plummeted by 92.44% to $1.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for IFRX at $1.5 million in Q4 2025, $19.7 million in Q4 2024, and $13.7 million in Q4 2023.